NCT06354218View on ClinicalTrials.gov

Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2027

Conditions
Esophageal Carcinoma
Interventions
DRUG

Serplulimab

Serplulimab （4.5mg/Kg every 3 weeks）

Trial Locations (1)

210009

RECRUITING

The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER